COMMUNIQUÉS West-GlobeNewswire

Adverum Biotechnologies to Participate in the 2025 RBC Capital Markets Ophthalmology Virtual Conference
31/03/2025
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular [...]
American Shared Hospital Services Announces Fourth Quarter and Full Year 2024 Earnings Conference Call
31/03/2025
Call Scheduled April 4th at 1:00 PM ET SAN FRANCISCO, March 31, 2025 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery and [...]
Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025
31/03/2025
Conference call today, March 31, 2025 at 4:30 PM ET SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended [...]
Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
31/03/2025
— Data demonstrated multiple clinical benefits beyond linear growth — NDA supported by data from three randomized, double-blind, placebo-controlled clinical trials in children with achondroplasia, with up to three years [...]
Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
31/03/2025
The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025 VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025 Presented encouraging preliminary [...]
Positron Corporation Secures $8 Million in Capital to Accelerate Growth and Market Expansion
31/03/2025
Niagara Falls, NY, March 31, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (OTC: POSC) (the “Company”), a leading molecular imaging medical device company specializing in Positron Emission Tomography (PET) and PET-CT [...]
Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference
31/03/2025
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to participate in a fireside chat at [...]
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties
31/03/2025
WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that [...]
Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
31/03/2025
-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron ® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial - - Halneuron ® CINP P2b study interim data readout is expected in Q4 2025 - - [...]
BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today
31/03/2025
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies [...]
IBA – ACQUISITION OF OWN SHARES
31/03/2025
Immediate Release – March 31 st , 2025 Louvain-la-Neuve, Belgium, March 31 st , 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion [...]
IBA – ACQUISITION D’ACTIONS PROPRES
31/03/2025
Publication immédiate – 31 mars 2025 Louvain-la-Neuve, Belgique, 31 mars 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam [...]
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
31/03/2025
More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® (risperidone) [...]
CORRECTION - Vaso Corporation Announces Financial Results for Fourth Quarter and Full Year 2024
31/03/2025
The Company Reports Continued Growth in Annual Revenue PLAINVIEW, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Please note that, in a release issued under the same headline earlier today by Vaso Corporation (OTCQX: VASO), [...]
Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies
31/03/2025
BOSTON, Mass, March 31, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc. (“Radiance” or the “Company”), a clinical stage biopharmaceutical company advancing Antibody Drug Conjugates (‘ADCs’), today announced that the U [...]
Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
31/03/2025
MEDIA RELEASE NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and [...]
PracticeLink Announces New “First Practice Fund” Scholarship to Support Physicians
31/03/2025
ST. LOUIS and HINTON, West Virginia, March 31, 2025 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, announces its [...]
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
31/03/2025
Media Release COPENHAGEN, Denmark; March 31, 2025 TIVDAK ® is the first and only antibody-drug conjugate (ADC) approved to treat recurrent or metastatic cervical cancer with disease progression on or after systemic [...]
Zelluna ASA [ZLNA]: Registration of reverse share split
31/03/2025
Oslo, Norway, 31 March, 2025 Reference is made to the stock exchange notice published by the Zelluna ASA (the " Company ") on 27 March 2025 with key information concerning a reverse share split in the ratio of 10:1. The [...]

Pages